[article]
| Titre : |
Social attention to activities in children and adults with autism spectrum disorder: effects of context and age |
| Type de document : |
Texte imprimé et/ou numérique |
| Auteurs : |
Dzmitry A. KALIUKHOVICH, Auteur ; Nikolay V. MANYAKOV, Auteur ; Abigail BANGERTER, Auteur ; Seth NESS, Auteur ; Andrew SKALKIN, Auteur ; Matthew S GOODWIN, Auteur ; Geraldine DAWSON, Auteur ; Robert L. HENDREN, Auteur ; Bennett L. LEVENTHAL, Auteur ; Caitlin M. HUDAC, Auteur ; Jessica BRADSHAW, Auteur ; Frederick SHIC, Auteur ; Gahan PANDINA, Auteur |
| Article en page(s) : |
79 p. |
| Langues : |
Anglais (eng) |
| Mots-clés : |
Activity monitoring Autism spectrum disorder Biomarkers Eye tracking Social attention Skalkin (at the time of study conduct), and Gahan Pandina are employees of Janssen Research & Development, LLC and hold company stocks/stock options. Matthew Goodwin has received research and consulting funding from Janssen Research & Development, LLC. Geraldine Dawson is on the Scientific Advisory Boards of Janssen Research and Development, Akili, Inc., LabCorp, Inc., and Roche Pharmaceutical Company, a consultant for Apple, Inc, Gerson Lehrman Group, Guidepoint, Inc., Teva Pharmaceuticals, Tris Pharma, Inc., and Axial Ventures, has received grant funding from Janssen Research and Development, and is CEO of DASIO, LLC. Dawson has developed technology that has been licensed and Dawson and Duke University have benefited financially. Dawson receives royalties from Guilford Press, Springer, and Oxford University Press. Robert Hendren received reimbursement for consultation from Janssen Research & Development, LLC. Bennett Leventhal has received research grant funding from the NIH, is a consultant to Janssen Research and Development, LLC and the Illinois Children’s Healthcare Foundation, and is a board member of the Brain Research Foundation. Frederick Shic is on the Scientific Advisory Board of and is a consultant to Janssen Research and Development, LLC, and has received grant funding from Janssen Research and Development LLC, and Roche. |
| Index. décimale : |
PER Périodiques |
| Résumé : |
BACKGROUND: Diminished visual monitoring of faces and activities of others is an early feature of autism spectrum disorder (ASD). It is uncertain whether deficits in activity monitoring, identified using a homogeneous set of stimuli, persist throughout the lifespan in ASD, and thus, whether they could serve as a biological indicator ("biomarker") of ASD. We investigated differences in visual attention during activity monitoring in children and adult participants with autism compared to a control group of participants without autism. METHODS: Eye movements of participants with autism (n?=?122; mean age [SD]?=?14.5 [8.0] years) and typically developing (TD) controls (n?=?40, age?=?16.4 [13.3] years) were recorded while they viewed a series of videos depicting two female actors conversing while interacting with their hands over a shared task. Actors either continuously focused their gaze on each other's face (mutual gaze) or on the shared activity area (shared focus). Mean percentage looking time was computed for the activity area, actors' heads, and their bodies. RESULTS: Compared to TD participants, participants with ASD looked longer at the activity area (mean % looking time: 58.5% vs. 53.8%, p??60] limited the ability to include individuals with substantial intellectual disability. CONCLUSIONS: Differences in attention to faces could constitute a feature discriminative between individuals with and without ASD across the lifespan, whereas between-group differences in looking at activities may shift with development. These findings may have applications in the search for underlying biological indicators specific to ASD. Trial registration ClinicalTrials.gov identifier NCT02668991. |
| En ligne : |
http://dx.doi.org/10.1186/s13229-020-00388-5 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=433 |
in Molecular Autism > 11 (2020) . - 79 p.
[article] Social attention to activities in children and adults with autism spectrum disorder: effects of context and age [Texte imprimé et/ou numérique] / Dzmitry A. KALIUKHOVICH, Auteur ; Nikolay V. MANYAKOV, Auteur ; Abigail BANGERTER, Auteur ; Seth NESS, Auteur ; Andrew SKALKIN, Auteur ; Matthew S GOODWIN, Auteur ; Geraldine DAWSON, Auteur ; Robert L. HENDREN, Auteur ; Bennett L. LEVENTHAL, Auteur ; Caitlin M. HUDAC, Auteur ; Jessica BRADSHAW, Auteur ; Frederick SHIC, Auteur ; Gahan PANDINA, Auteur . - 79 p. Langues : Anglais ( eng) in Molecular Autism > 11 (2020) . - 79 p.
| Mots-clés : |
Activity monitoring Autism spectrum disorder Biomarkers Eye tracking Social attention Skalkin (at the time of study conduct), and Gahan Pandina are employees of Janssen Research & Development, LLC and hold company stocks/stock options. Matthew Goodwin has received research and consulting funding from Janssen Research & Development, LLC. Geraldine Dawson is on the Scientific Advisory Boards of Janssen Research and Development, Akili, Inc., LabCorp, Inc., and Roche Pharmaceutical Company, a consultant for Apple, Inc, Gerson Lehrman Group, Guidepoint, Inc., Teva Pharmaceuticals, Tris Pharma, Inc., and Axial Ventures, has received grant funding from Janssen Research and Development, and is CEO of DASIO, LLC. Dawson has developed technology that has been licensed and Dawson and Duke University have benefited financially. Dawson receives royalties from Guilford Press, Springer, and Oxford University Press. Robert Hendren received reimbursement for consultation from Janssen Research & Development, LLC. Bennett Leventhal has received research grant funding from the NIH, is a consultant to Janssen Research and Development, LLC and the Illinois Children’s Healthcare Foundation, and is a board member of the Brain Research Foundation. Frederick Shic is on the Scientific Advisory Board of and is a consultant to Janssen Research and Development, LLC, and has received grant funding from Janssen Research and Development LLC, and Roche. |
| Index. décimale : |
PER Périodiques |
| Résumé : |
BACKGROUND: Diminished visual monitoring of faces and activities of others is an early feature of autism spectrum disorder (ASD). It is uncertain whether deficits in activity monitoring, identified using a homogeneous set of stimuli, persist throughout the lifespan in ASD, and thus, whether they could serve as a biological indicator ("biomarker") of ASD. We investigated differences in visual attention during activity monitoring in children and adult participants with autism compared to a control group of participants without autism. METHODS: Eye movements of participants with autism (n?=?122; mean age [SD]?=?14.5 [8.0] years) and typically developing (TD) controls (n?=?40, age?=?16.4 [13.3] years) were recorded while they viewed a series of videos depicting two female actors conversing while interacting with their hands over a shared task. Actors either continuously focused their gaze on each other's face (mutual gaze) or on the shared activity area (shared focus). Mean percentage looking time was computed for the activity area, actors' heads, and their bodies. RESULTS: Compared to TD participants, participants with ASD looked longer at the activity area (mean % looking time: 58.5% vs. 53.8%, p??60] limited the ability to include individuals with substantial intellectual disability. CONCLUSIONS: Differences in attention to faces could constitute a feature discriminative between individuals with and without ASD across the lifespan, whereas between-group differences in looking at activities may shift with development. These findings may have applications in the search for underlying biological indicators specific to ASD. Trial registration ClinicalTrials.gov identifier NCT02668991. |
| En ligne : |
http://dx.doi.org/10.1186/s13229-020-00388-5 |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=433 |
|
Faire une suggestion Affiner la rechercheEvaluating heterogeneity in ASD symptomatology, cognitive ability, and adaptive functioning among 16p11.2 CNV carriers / Caitlin M. HUDAC in Autism Research, 13-8 (August 2020)
